Bluebird Bio, Inc. [BLUE]

Source: 

Company Overview

Bluebird Bio, Inc. is a biotechnology company committed to researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on our proprietary lentiviralBluebird Bio, Inc. is a biotechnology company committed to researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on our proprietary lentiviral vector gene addition platform. In 2022, following more than a decade of leadership in research and clinical development, we received approval from the US Food and Drug Administration for two gene therapies: ZYNTEGLO and SKYSONA.